Altimmune Inc (NASDAQ: ALT) open the trading on Wednesday, with great promise as it jumped 4.24% to $4.18, before settling in for the price of $4.01 at the close. Taking a more long-term approach, ALT posted a 52-week range of $2.90-$7.73.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 3.48%. Meanwhile, its Annual Earning per share during the time was 3.48%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 27.05%. This publicly-traded company’s shares outstanding now amounts to $104.34 million, simultaneously with a float of $103.59 million. The organization now has a market capitalization sitting at $436.15 million.
Altimmune Inc (ALT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Altimmune Inc’s current insider ownership accounts for 0.71%, in contrast to 40.00% institutional ownership. According to the most recent insider trade that took place on Jan 08 ’26, this organization’s Director bought 5,000 shares at the rate of 4.08, making the entire transaction reach 20,410 in total value, affecting insider ownership by 13,498. Preceding that transaction, on Dec 29 ’25, Company’s Director bought 527 for 3.80, making the whole transaction’s value amount to 2,003. This particular insider is now the holder of 527 in total.
Altimmune Inc (ALT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
Altimmune Inc’s EPS increase for this current 12-month fiscal period is 27.05% and is forecasted to reach -1.23 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 9.04% through the next 5 years, which can be compared against the 3.48% growth it accomplished over the previous five years trading on the market.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Let’s observe the current performance indicators for Altimmune Inc (ALT). It’s Quick Ratio in the last reported quarter now stands at 17.18. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 21807.40.
In the same vein, ALT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.07, a figure that is expected to reach -0.24 in the next quarter, and analysts are predicting that it will be -1.23 at the market close of one year from today.
